SCHEMBL557414

SCHEMBL557414

O=C(O)c1ccn2ccnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.44
KDM4E B2RXH2 2/20 0.44
KDM6B O15054 2/20 0.44
KDM4A O75164 2/20 0.44
KDM5C P41229 2/20 0.44
KDM2A Q9Y2K7 2/20 0.44
KDM3A Q9Y4C1 2/20 0.44
KDM5A P29375 2/20 0.44
TET3 O43151 1/20 0.44
BBOX1 O75936 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
ASPH Q12797 1/20 0.44
KDM4D Q6B0I6 1/20 0.44
TET2 Q6N021 1/20 0.44
ALKBH5 Q6P6C2 1/20 0.44
KDM7A Q6ZMT4 1/20 0.44
KDM8 Q8N371 1/20 0.44
TET1 Q8NFU7 1/20 0.44
EGLN2 Q96KS0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23089217 0.98 KDM4C (0.43) KDM4CKDM4EKDM6BKDM4AKDM5C
SCHEMBL556729 0.84 PIK3C3 (0.43) KDM5CKDM5BPIK3C3NAMPTHSD11B1
SCHEMBL10138744 0.84 NTRK1 (0.48) MAPTPIK3C3NAMPTHSD11B1SSTR4
SCHEMBL1793919 0.81 NAMPT (0.48) KDM4EEGLN2PIK3C3NAMPTHSD11B1
SCHEMBL13337090 0.80 NAMPT (0.39) PIK3C3NAMPTHSD11B1JMJD6SSTR4
SCHEMBL14144286 0.80 NAMPT (0.42) PIK3C3NAMPTHSD11B1SSTR4
SCHEMBL12664206 0.80 SSTR4 (0.43) PIK3C3NAMPTHSD11B1SSTR4
SCHEMBL20646940 0.80 KDM4E (0.42) KDM4EPIK3C3NAMPTHSD11B1SSTR4
SCHEMBL376440 0.80 JMJD6 (0.48) KDM4CKDM4EKDM6BKDM5CKDM2A
SCHEMBL15176490 0.80 NAMPT (0.47) PIK3C3NAMPTHSD11B1SSTR4TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661811-A Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof 江南大学 2025-03-21 CN claimed
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2310356-B1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME LUNDBECK & CO AS H (DK) 2013-08-14 EP claimed
US-8389519-B2 Adamantyl diamide derivatives and uses of same H. LUNDBECK A/S (DK) 2013-03-05 US claimed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP claimed
US-8198275-B2 Adamantyl diamide derivatives and uses of same H. LUNDBECK A/S (DK) 2012-06-12 US claimed
JP-2011529057-A 2011-12-01 JP claimed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO claimed
WO-2010011570-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 WO claimed
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 US claimed
EP-1546112-A4 IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC INC (US) 2006-06-07 EP claimed
EP-1546112-A2 IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME Biogen Idec MA Inc. (US) 2005-06-29 EP claimed
WO-2004021989-A2 IMIDAZOLOPYRIDINES AND METHODS OF MAKING AND USING THE SAME BIOGEN IDEC MA INC. (US) 2004-03-18 WO claimed
EP-4698530-A1 NK3 MODULATORS AND USES THEREOF Kallyope, Inc. (US) 2026-02-25 EP disclosed
US-20250263410-A1 NK3 MODULATORS AND USES THEREOF KALLYOPE, INC. 2025-08-21 US disclosed
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases ONCO3R THERAPEUTICS BV (BE) 2025-08-19 US disclosed
EP-1557411-A1 N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2005-07-27 EP disclosed
US-6303593-B1 FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS MERCK & CO., INC. 2001-10-16 US disclosed
WO-2000051608-A1 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263410-A1 NK3 MODULATORS AND USES THEREOF TAC3, TACR3, TACR2 KDM4C 3673/4885KDM4E 3478/4885KDM6B 3387/4885
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME QDPR, ADM2, PDE3B KDM4C 2427/4885KDM4E 2749/4885KDM6B 2481/4885
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 KDM4C 1549/4885KDM4E 883/4885KDM6B 1488/4885
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases IL5, IL15, IL1A KDM4C 1037/4885KDM4E 3302/4885KDM6B 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.